ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 452

Anti-citrullinated Vimentin Antibodies Are Associated to Early Deterioration of Cortical Bone and Volumetric Bone Mineral Density in Finger Joints in RA-at-risk Patients

Georg Schett1, David Simon 2, Axel Hueber 2, Holger Bang 3, Jürgen Rech 4, Gerhard Kroenke 5 and Arnd Kleyer 6, 1Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany, 2Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, 3Orgentec Diagnostika, 55129 Mainz, Germany, Mainz, 4Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany, 5Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Austria, 6Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: ACPA, anti-mutated citrullinated vimentin, Bone and imaging techniques

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Autoimmunity, characterized by the presence of anti-modified protein antibodies (AMPA), recognizing citrullinated, carbamylated or acetylated proteins, as well as rheumatoid factor (RF) precedes the onset of manifest rheumatoid arthritis (1,2).High resolution peripheral quantitative (HR-pQCT) technique is able to visualize  marginal cortical changes in peripheral joints (3).To evaluate presence of deterioration of cortical bone as well as volumetric bone mineral density in finger joints using HR-pQCT technique and correlate these findings to arthritis specific autoimmunity, particularly osteoclast-inducing citrullinated vimentin (cVIM) antibodies and their impact on the later development of RA.

Methods: Patients were part of our individuals at risk cohort Erlangen (ethics approval 333_16B) comprising patients with AMPAs but without clinical manifest arthritis. These patients are regularly followed for arthritis development. Patients receive HR-pQCT scans as part of the protocol analyzing cortical micro-channels (CoMiCs) as well as volumetric cortical and trabecular bone densities of MCP joints as described before (3). Anti-modified protein antibody (AMPA) response was profiled including reactivities against citrullinated proteins (vimentin, enolase, fibrinogen) as well as carbamylated and acetylated vimentin from serum samples at time points

Results: 75 RA at risk patients were included. Patients with high-level ( >1000U) cVIM antibodies showed a broader AMPA response. Those patients also displayed more severe deterioration of cortical bone (higher CoMiCs, lower cortical and trabecular bone volume) compared to subjects with low/no cVIM reactivity. High cVIM antibodies and microstructural changes ( >15 radial CoMiCs/joint) were associated with the presence of arthralgia. Furthermore, progression to RA was high in subjects with

high cVIM (53%) vs. those with low (22%) or no (5%) antibodies and those with microstructural changes (46%) vs. those without such changes (16%).

Conclusion: HR-pQCT technique detects earliest deterioration of cortical bone and volumetric bone mineral density in finger Joints with association to cVIM antibodies. These data support the concept of a non-silent form of autoimmunity regarding bone changes before the onset of RA.


Disclosure: G. Schett, AbbVie, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, 8, AbbVie, BMS, Celgene, Janssen, Lilly, Novartis, UCB, 5, BMS, Celgene, GSK, Lilly, Novartis, 2; D. Simon, None; A. Hueber, None; H. Bang, Orgentec, 3; J. Rech, AbbVie, 8, Biogen, 8, BMS, 5, 8, Celgene, 5, 8, Chugai, 5, MSD, 8, Novartis, 5, 8, Roche, 5; G. Kroenke, None; A. Kleyer, None.

To cite this abstract in AMA style:

Schett G, Simon D, Hueber A, Bang H, Rech J, Kroenke G, Kleyer A. Anti-citrullinated Vimentin Antibodies Are Associated to Early Deterioration of Cortical Bone and Volumetric Bone Mineral Density in Finger Joints in RA-at-risk Patients [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/anti-citrullinated-vimentin-antibodies-are-associated-to-early-deterioration-of-cortical-bone-and-volumetric-bone-mineral-density-in-finger-joints-in-ra-at-risk-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-citrullinated-vimentin-antibodies-are-associated-to-early-deterioration-of-cortical-bone-and-volumetric-bone-mineral-density-in-finger-joints-in-ra-at-risk-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology